Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized β-Lactamases

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1313-1319

  Mushtaq, Shazad ^a   Ge, Yigong ^b   Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Peninsula Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; OXA CARBAPENEMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG;

ACINETOBACTER; AMPC GENE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM CONJUGATION; BACTERIUM ISOLATE; BACTERIUM MUTANT; CITROBACTER FREUNDII; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROBACTER; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERRATIA MARCESCENS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CHROMOSOMES, BACTERIAL; CONJUGATION, GENETIC; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; PLASMIDS;

EID: 1642502313     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1313-1319.2004     Document Type: Article

References (24)

1. Afzal-Shah, M., N. Woodford, and D. M. Livermore. 2001. Characterization of OXA-25, OXA-26 and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45:583-588.
2. Babini, G. S., and D. M. Livermore. 2000. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J. Antimicrob. Chemother. 45:183-189.
3. Chow, J. W., M. J. Fine, D. M. Shlaes, J. P. Quinn, D. C. Hooper, M. P. Johnson, R. Ramphal, M. M. Wagener, D. K. Miyashiro, and V. L. Yu. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:585-590.
4. Chu, Y.-W., M. Aftal-Shah, E. T. S. Houang, M.-F. I. Palepou, D. J. Lyon, N. Woodford, and D. M. Livermore. 2001. IMP-4, a novel metallo-β -lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob. Agents Chemother. 45:710-714.
5. Dalla Costa, L. M., J. M. Coelho, H. A. Souza, M. E. S. Castro, C. J. N. Stier, K. L. Bragagnolo, A. Rea-Neto, S. R. Penteado-Filho, D. M. Livermore, and N. Woodford. 2003. Outbreak of carbapenem-resistant Acinetobacter baumannii producing OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol. 41: 3403-3406.
6. Edwards, J. R., and M. J. Betts. 2000. Carbapenems: the pinnacle of the β-lactam antibiotics or room for improvement? J. Antimicrob. Chemother. 45:1-4.
7. Henwood, C. J., T. Gatward, M. Warner, D. James, M. W. Stockdale, R. Spence, K. J. Towner, D. M. Livermore, and N. Woodford. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49:479-487.
8. Iso, Y., T. Irie, Y. Nishino, K. Motokawa, and Y. Nishitani. 1996. A novel 1 β-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 β-methylcarbapenems. J. Antibiot. (Tokyo) 49:199-209.
9. Kohler, J., K. L. Dorso, K. Young, G. G. Hammond, H. Rosen, H. Kropp, and L. L. Silver. 1999. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 43:1170-1176.
10. Livermore, D. M. 2003. Threat from the pink corner. Ann. Med. 35:226-234.
11. Livermore, D. M., A. M. Sefton, and G. M. Scott. 2003. Properties and potential of ertapenem. J. Antimicrob Chemother. 52:331-344.
12. Livermore, D. M., K. J. Oakton, M. W. Carter, and M. Warner. 2001. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrob. Agents Chemother. 45:2831-2837.
13. Livermore, D. M., and M. Yuan. 1996. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J. Antimicrob. Chemother. 38:409-424.
14. Lopez-Otsoa, F., L. Gallego, K. J. Towner, L. Tysall, N. Woodford, and D. M. Livermore. 2002. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J. Clin. Microbiol. 40:4741-4743.
15. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
16. Mikamo, H., K. Izumi, Y. X. Hua, Y. Hayasaki, Y. Sato, and T. Tamaya. 2000. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J. Antimicrob. Chemother. 46:471-474.
17. Mori, M., M. Hikida, T. Nishihara, T. Nasu, and S. Mitsuhashi. 1996. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. 37:1034-1036.
18. National Committee for Clinical Laboratory Standards. 2003. Methods of dilution antimicrobial susceptibility testing of bacteria that grow aerobically. M07-A6. Approved standard, 6th ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
19. Tsuji, M., Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42:94-99.
20. Tysall, L., M. W. Stockdale, P. R. Chadwick, M. F. Palepou, K. J. Towner, D. M. Livermore, and N. Woodford. 2002. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the United Kingdom. J. Antimicrob. Chemother. 49:217-218.
21. Yan, J. J., W. C. Ko, C. L. Chuang, and J. J. Wu. 2002. Metallo-β-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacterfreundii. J. Antimicrob. Chemother. 50:503-511.
22. Yang, Y., and D. M. Livermore. 1988. Chromosomal β-lactamase expression and resistance to β-lactam antibiotics in Proteus vulgaris and Morganella morganii. Antimicrob. Agents Chemother. 32:1385-1391.
23. Yang, Y. J., and D. M. Livermore. 1989. Interactions of meropenem with class I chromosomal β-lactamases. J. Antimicrob. Chemother. 24(Suppl. A): 207-217.
24. Yang, Y. J., P. Wu, and D. M. Livermore. 1990. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob. Agents Chemother. 34:755-758.